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Background: Successful crossing of superﬁcial femoral artery (SFA) and below the
knee (BTK) chronic total occlusions (CTO) often involves careful selection of a
primary crossing strategy. We compared CTO crossing success rates with a primary
wire-catheter or crossing device use.
Methods: We analyzed a total of 439 SFA and BTK CTO interventions in 316 pa-
tients enrolled in the multicenter Excellence in Peripheral Artery Disease (XLPAD)
registry (NCT01904851) between July 2005 and May 2014.
Results: A total of 295 (67.4%) procedures utilized a primary wire-catheter and 143
(32.6%) a primary crossing device. The crossing devices used were 52% Viance
(Covidien Inc., Dublin, Ireland), 32% Frontrunner (Cordis Corp., Bridgewater, NJ),
10% TruePath (Boston Scientiﬁc, Natick, MA), and 6% other. Both groups were
matched for lesion length (134.2 mm vs. 136.9 mm; p¼0.730) and location (82.8%
SFA vs. 79.7% SFA; p¼0.432). Primary crossing success was 51.9% in the ’wire-
catheter’ group; while 28.1% and 26.8% required provisional crossing or re-entry
devices, respectively. Primary success with a crossing device was 72.1% (Figure 1).
Provisional use of crossing device was higher in diabetics (55% vs. 42%; p¼0.044),
longer lesions (156.3  76.9 mm vs. 125.2  69.1 mm; p¼0.003), and in patients with
lower ankle-brachial indices (0.630.27 vs. 0.74  0.32; p¼0.011).Conclusions: Although most operators select a primary wire-catheter strategy to cross
infrainguinal CTO, primary crossing success is higher with crossing device use.
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Background:
Methods: The safety and efﬁcacy of the Misago superﬁcial femoral artery (SFA)
stent was evaluated prospectively in this initial collaboration trial between JapanJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Ilia(JP) and the United States (US) (Misago,Terumo corp., Tokyo, Japan). Since this
trial enrolled patients mainly from JP and US, and since there is question as to
whether race difference exists in SFA stent performance, the race-difference on
outcome was also analyzed. In addition, results were compared with a prior SFA
stent trial.
Results: The Misago stent was implanted in 261subjects with TASC A/B SFA
lesions (201 subjects in US, 50 in JP, 9 in Taiwan, 1 in South Korea). The mean
patient age was 69.3+/-10.0 and mean lesion length was 8.38+/-4.13 cm. The
overall 12 months primary patency rate and clinically driven TLR were 82.9% and
13.0%, respectively. When these results were compared with the Zilver PTX trial,
there were no difference in primary patency rate (OSPREY 82.9% vs Zilver PTX
89.9%; P¼0.206), non-TLR (87.0% vs 90.5%; P¼0.252) and stent fracture rate
(1.3% vs 0.9%; P¼0.694), however, stent thrombosis rate was statistically less
common in OSPREY (0.4% vs 2.7%; P< 0.05) (Zilver PTX, Cook Medical,
Bloomington,IN). As far as race difference within OSPREY trial, outcome between
US and non- US patients were similar including primary patency (82.9% versus
83.0%; P¼0.889), clinically driven TLR (13.4% versus 11.7%; P¼0.829), stent
fracture rate (1.5% versus 0.0%; P¼1.000) and stent thrombosis rate (0.5% versus
0.0%; P¼1.000).
Conclusions: OSPREY 12 months data showed satisfactory outcome of the Misago
stent for the treatment of TASC A/B SFA lesions and appears to be comparable to
drug eluting stent experience. In addition, the lack of difference in outcome among
race supports the value of international trials.
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Background: Femoropopliteal stenting for treatment of peripheral arterial disease has
shown superiority to balloon angioplasty (PTA) for the treatment of lifestyle limiting
claudication and critical limb ischemia. However, in-stent restenosis (ISR) after
femoropopliteal artery stenting remains a challenging therapeutic problem due pro-
cedural complications and repeat restenosis of up to 50%.
Methods: EXCITE ISR is a multi-center, prospective, randomized, controlled trial
comparing Excimer Laser Atherectomy (ELA; Spectranetics, Inc.) with adjunctive
PTA to PTA alone for the treatment of femoropopliteal ISR. A total of 335 patients
were planned for enrollment utilizing a 2:1 randomization structure (ELA +PTA:
PTA) at 40 centers in the United States. Primary inclusion criteria were Rutherford
class 1 to 4, total target treatment length  4 cm, vessel diameter 5-7 mm, and lesion
entirely crossable by an intraluminal guidewire. Primary endpoints were freedom from
major adverse event (MAE) through 30 days post-procedure and freedom from target
lesion revascularization (TLR) through 6 month follow up.
Results: Both groups were similar in baseline demographics and lesion characteris-
tics. Patients were predominantly male (63%) while nearly half were diabetic (47%)
and had a history of ISR (30%). Lesion length averaged 19 cm with 30% total oc-
clusion. The trial was stopped at 250 enrolled patients after successful primary
endpoint analysis. ELA + PTA demonstrated better procedural success with a sig-
niﬁcant reduction in procedural complications and post-treatment stenosis as
compared to PTA alone. The primary safety and efﬁcacy endpoints established su-
periority of ELA + PTA as compared to PTA alone.
Conclusions: The EXCITE ISR study is the ﬁrst trial conducted under an IDE to
support an FDA indication for femoropopliteal ISR. The complete 6 month results will
be provided to show that ELA + PTA is superior to PTA alone in the treatment of
femoropopliteal ISR.
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Background: Recent studies have reported higher 1-year primary patency and
lower rates of target lesion revascularization after endovascular treatment ofc and SFA B155
